Correlation Between 25-hydroxy-Vitamin D and Parkinson's Disease: A Case-Control study

ming xia
  Xinjiang Medical University Affiliated First Hospital

wenjuan Xiu
  Xinjiang Medical University Affiliated First Hospital

Xuliang Wang
  xinjiang red star hospital

Tingting Wu
  Xinjiang Medical University Affiliated First Hospital

Yingying Zheng
  Xinjiang Medical University Affiliated First Hospital

Yitong Ma
  Xinjiang Medical University Affiliated First Hospital

Xiang Xie
  Xinjiang Medical University Affiliated First Hospital

Jiuqing Zhou (zhouqingjiu007@163.com)

Research

Keywords: Vitamin D, Parkinson's disease, 25-hydroxy vitamin D

DOI: https://doi.org/10.21203/rs.3.rs-38762/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Previous cross-sectional studies have shown that Parkinson's disease (PD) patients have lower serum 25-hydroxy vitamin D (25(OH)D) concentrations than controls. Whether the research in other regions' findings are generalizable to China populations remains untested in other studies. In this case-control study we examined the correlation between 25-hydroxy-vitamin D and Parkinson's disease.

**Methods:** We establish an association between deficiency of 25-hydroxy-vitamin D and PD in a case-control study of 100 PD patients and 100 control subjects free of neurologic disease in the First Affiliated Hospital of Xinjiang Medical University.

**Results:** Total 25-hydroxy-vitamin D levels, were deficient in 21% of patients with PD compared with 4% of controls. In univariate analyses Plasma levels of 25-hydroxy-vitamin D were associated with PD (p<0.001), respectively. In multivariate analyses, Vitamin D deficiency (25(OH)D <20 ng/mL) were significant associated with PD (p=0.008, OR=17.13, 95% CI, 2.082-141.075). Individuals with levels in the lowest quartile of 25(OH)D values had the highest prevalence of PD (p=0.026, OR=11.786, 95% CI, 1.342-103.51) compared with individuals with values in the highest quartile.

**Conclusions:** Our study reveals an association between 25-hydroxy-vitamin D and PD. Patients with incident PD had significantly lower serum 25(OH)D concentrations than age-matched controls, High-risk PD patients with vitamin D deficiency who have not yet developed exercise impairment, these populations should undergo vitamin D measurement and vitamin D treatment as soon as possible.

**Background**

Parkinson's disease (PD) is a common neurodegenerative disorder that the incidence and disability continue to increase as the population ages[1]. Although both genetic and environmental factors have been implicated, its etiological factors are mostly unknown[2]. Recently, among the many pathogenesis of Parkinson's disease, people found a commonality {25-hydroxy-vitamin D [25 (OH) D] deficiency}, which suggests there is a correlation between 25 (OH) D levels and Parkinson's. Evatt[3] et al. retrospective cross-sectional cohort study found demonstrates a significantly higher prevalence of hypovitaminosis in PD vs both healthy controls and patients with AD. Ding [4] et al. study showed that vitamin D deficiency in 17.6% of cases (68/388) compared with 9.3% of controls (26/283; p = 0.002), Plasma levels of 25-hydroxy-vitamin D3 were associated with the prevalence of PD in both univariate and multivariate analyses (P = 0.0034; P = 0.047). The Mini-Finland Health Survey, people in the lowest quartile at baseline had approximately three times the risk of developing PD compared with people in the highest quartile [5].

Sun-light exposure is the major source for vitamin D [6]. The production of vitamin D depends not only on the intensity of ultraviolet rays, but also on the duration of ultraviolet irradiation [7] and there are differences between different regions and races. Wang [8] et al. Case-control studies found that a significant positive correlation between serum 25(OH)D and sunlight exposure, lower levels of serum 25(OH)D and sunlight exposure are significantly associated with an increased risk for PD. A few case-
control studies in Finland, Iran, Japan and the United States have reported lower 25(OH)D levels in PD patients compared with age-matched controls [9–11].

- Affected by the region, the annual sunshine hours in Xinjiang, China are 3200–3300, and the average annual sunshine hours under standard illumination are 5.08–6.3, which is higher than that in other regions of China [12]. Whether the research in other regions' findings are generalizable to China populations remains untested in other studies. To address these limitations in previous investigations, in our study, we used immunoassay-based vitamin D measuring assays to investigate an association between deficiency of the 25(OH)D and PD in the First Affiliated Hospital of Xinjiang Medical University from January 2019 to December 2019.

Methods

Study Design and Population

In our study, we collected 100 with PD and 100 control subjects without neurologic disease nested in the First Affiliated Hospital of Xinjiang Medical University from January 2019 to December 2019. Inclusion criteria for PD cases were conforms to the new standard for clinical diagnosis of Parkinson's disease of the International Dyskinesia Association [13]. Exclusion criteria for PD cases were diagnosis of endocrine system diseases such as hyperparathyroidism and other diseases of abnormal calcium and phosphorus metabolism, fractures or bone tumors recently (≤ 6 months); known active ulcer, or active colitis. Inclusion criteria for healthy controls were no current diagnosis or history of a neurologic disease. Exclusion criteria for controls were the same as for cases. Controls were comparable to the PD cases in that they were drawn from the same source population and could be identified as cases, if they had disease.

This study protocol was approved by the institutional review boards of Ethics Committee of First Affiliated Hospital of Xinjiang Medical University. This study is a retrospective study, we don't need to obtain informed consent from eligible patients.

Clinical and Demographic Characteristics Collection

Baseline characteristics of cases and controls were examined (Table 1), including factors known to affect vitamin D status such as age, sex, race, smoking status, uric acid, blood calcium, fasting blood glucose, glycated hemoglobin.
Table 1  
Baseline characteristics of the study populations

|                       | PD (100)       | Control (100)  | P-Value  |
|-----------------------|----------------|----------------|----------|
| Age, y                | 65.86 ± 10.00  | 52.88 ± 9.39   | < 0.001<sup>a</sup> |
| Males                 | 54(54)         | 45(45)         | 0.203    |
| Race (Han)            | 73(73)         | 65(65)         | 0.221    |
| Hypertension          | 47(47)         | 49(49)         | 0.777    |
| Blood calcium         | 2.26 ± 0.12    | 2.27 ± 0.10    | 0.523    |
| Fasting blood glucose | 5.27 ± 1.31    | 5.15 ± 1.61    | 0.571    |
| LDL-C                 | 2.48 ± 0.82    | 2.62 ± 0.86    | 0.221    |
| Cystatin C            | 0.83 ± 0.21    | 0.77 ± 0.20    | 0.057    |

**Clinical criteria**

|                        | PD (100)       | Control (100)  | P-Value  |
|------------------------|----------------|----------------|----------|
| Age at onset, y        | 62.15 ± 1.06   |                |          |
| Duration, y            | 4.09 ± 0.48    |                |          |
| Hoehn and Yahr stage   | 2.25 ± 0.07    |                |          |
| 1                      | 11(11)         |                |          |
| 1.5                    | 17(17)         |                |          |
| 2                      | 25(25)         |                |          |
| 2.5                    | 15(15)         |                |          |
| 3                      | 27(27)         |                |          |
| 4                      | 5(5)           |                |          |
| 25(OH)D                | 32.39 ± 13.91  | 42.54 ± 17.72  | < 0.001<sup>a</sup> |
| < 20 ng/mL             | 21(21)         | 4(4)           | 0.007<sup>a</sup> |
| 20–29 ng/mL            | 27(27)         | 20(20)         | 0.234    |
| ≥ 30 ng/mL             | 52(52)         | 76(76)         | 0.033<sup>a</sup> |

Abbreviations: 25(OH) D = 25-hydroxy-vitamin D; LDL-C = low-density lipoprotein-cholesterol; PD = Parkinson disease;

<sup>a</sup> Statistically significant.

**25(OH)D Detection**
Using immunoassay-based vitamin D measuring assays at the central laboratory of The First Affiliated Hospital of Xinjiang Medical University.

**Statistical analysis.**

T-test and chi-square test were used to the comparison of Continuous variable and categorical variables. Total 25(OH)D was analyzed categorically, using the established clinical criteria for vitamin D deficiency (25(OH)D < 20 ng/mL), vitamin D insufficiency (25(OH)D 20–29 ng/mL), and vitamin D sufficient(25(OH)D ≥ 30 ng/mL), vitamin D sufficient (25(OH)D ≥ 30 ng/mL) as the reference. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated for each quartile individually, using the highest quartile as the reference. Logistic regression analysis was used to evaluate the association between vitamin D concentrations and PD, Hoehn and Yahr (HY) stage, PD auration, adjusting for age at sample draw. General linear regression models were used for testing associations of vitamin D duration of PD illness. All analyses were performed using the SPSS 26.0 for Mac statistical software (SPSS Inc, Chicago, Illinois, United States), and statistical significance was defined as p < 0.05.

**Results**

Table 1 shows several demographic characteristics of the subjects. The PD cases had a higher age (65.86 ± 10.00 years for cases vs 52.88 ± 9.39 years for controls), No significant differences in sex, race, Hypertension, blood calcium, fasting blood glucose, low-density lipoprotein-cholesterol (LDL-C), Cystatin C were found between cases and controls. In clinical criteria the PD cases Hoehn and Yahr (HY) stage was 2.25 ± 0.07. Compared with the control group, the total plasma 25 (OH)D level in the PD group was lower (32.39 ± 13.91 vs 42.54 ± 17.72 ng/mL, p < 0.001).

25(OH)D is the vitamin D metabolite that is measured to assess a patient’s vitamin D status. Vitamin D deficiency is diagnosed when 25(OH)D < 20 ng/mL [14,15], vitamin D insufficiency is defined as 25(OH)D of 21–29 ng/mL, and 25(OH)D > 30 ng/mL is considered sufficient [16]. In clinical, the average HY stage in the cases was 2.25 ± 0.07. In univariate analysis, the total 25 (OH)D level was lower than that in the control group (32.39 ± 13.91 vs 42.54 ± 17.72 ng/mL, p < 0.001). There was vitamin D deficiency in 21% of cases (21/100) compared with 4% of controls (4/100; p = 0.007). Furthermore, 27% of cases (27/100) were vitamin D insufficient compared with 20% of controls (20/100; p = 0.234).

Multivariate analysis (Table 2) adjusting for baseline of age, Vitamin D deficiency (25(OH)D < 20 ng/mL) were Significant associated with PD. The probability of vitamin D deficiency in PD patients is 17.13 times that of the control group (95% CI, 2.082-141.075). Low levels of 25 (OH)D are associated with increased disease prevalence. Individuals with levels in the lowest quartile of 25(OH)D values observed in our population had the highest prevalence of PD with an odds ratio of 11.786 with p = 0.026 (95% CI, 1.342-103.51) compared with individuals with values in the highest quartile (Table 2). After adjusting for these covariates, deficiency of total 25(OH)D remained enriched in PD with p = 0.016. HY stage (≥3 or ≥ 3) still differences (Figure)
Table 2
Multivariate analysis between total 25(OH) D with PD, and HY stage

| PD          | HY          | Duration | OR(95% CI)       | P-Value | β     | P-Value | β     | P-Value |
|-------------|-------------|----------|------------------|---------|-------|---------|-------|---------|
| Clinical cutoff analysis                      |           |          |                  |         |       |         |       |         |
< 20 ng/mL  | 17.13(2.082-141.075) | 0.008<sup>a</sup> | -1.238          | 0.522   | -20.844 | <0.001<sup>a</sup> |
20–29 ng/mL | 0.719(0.230-2.245)   | 0.570    | 0.042            | 0.979   | -1.362 | 0.357   |
≥ 30 ng/mL  | Ref         | Ref      | Ref              | Ref     | Ref    | Ref     |
Quartile analysis
Total 25(OH) D
Q1(7.5-19.31 ng/mL) | 11.786(1.342-103.51) | 0.026<sup>a</sup> | 27.849          | <0.001<sup>a</sup> | 23.223 | <0.001<sup>a</sup> |
Q2(19.31–30.43 ng/mL) | 0.974(0.316-2.998) | 0.963    | 4.195            | 0.012<sup>a</sup> | 2.413  | 0.087   |
Q3(30.43-40 ng/mL) | 0.459(0.138–1.528) | 0.204    | 0.983            | 0.281   | -0.345 | 0.733   |
Q4(> 40 ng/mL) | Ref         | Ref      | Ref              | Ref     | Ref    | Ref     |
Abbreviations: CI = confidence interval; HY = Hoehn and Yahr; 25(OH) D = 25-hydroxy-vitamin D; OR = odds ratio; PD = Parkinson disease; Ref. =reference

All relations are statistically adjusted for age.

<sup>a</sup> Statistically significant.

Finally, we examined the relationship between the duration of symptoms and vitamin D levels. Our data shows that the total 25 (OH) D concentration is related to the disease duration (P = 0.002)(Figure )

Discussion

This case-control study of 100 cases and 100 controls in The First Affiliated Hospital of Xinjiang Medical University from January 2019 to December 2019,provides compelling evidence that vitamin D deficiency
of PD patients is 17.13 times that in controls of similar ages without PD. Individuals with levels in the lowest quartile of 25(OH)D values had the highest prevalence of PD (p = 0.026, OR = 11.786, 95% CI, 1.342–103.51) compared with individuals with values in the highest quartile. To the best of our knowledge, this is the first study to investigate the relation between the deficiency of the 25(OH)D and PD in Xinjiang of China.

Several studies have reported an association of PD with lower plasma 25(OH)D concentrations [17–19]. Ding et al [4] study shows that there was vitamin D deficiency in 17.6% of cases (68/388) compared with 9.3% of controls (26/283; p = 0.002). After adjusting for age, sex, race, and vitamin D supplementation, deficiency of total 25(OH)D remained enriched in PD with p = 0.03. Wang et al [20] study shows that Vitamin D deficiency (total 25 (OH) D < 20 ng / mL) was significantly correlated with PD (P < 0.0001). The lowest quartile of 25(OH)D values had the highest prevalence of PD with an OR = 2.66, P < 0.0001 (95% CI, 1.746–4.03) compared with individuals with values in the highest quartile. Our study also draws results consistent with the above studies, in our case-control study, cases are 11.786 times as likely as controls to be in the lowest quartile compared with the highest quartile.

Suzuki et al [21] conducted a randomized, double-blind, placebo-controlled vitamin D intervention trial, the results showed that vitamin D significantly inhibited the deterioration of the Hoehn-Yahr staging score of PD patients compared with placebo. [difference between groups: P = 0.005; mean ± SD change within vitamin D3 group: +0.02 ± 0.62 (P = 0.79); change within placebo group: +0.33 ± 0.70 (P = 0.0006)]. It is suggested that vitamin D has a delaying effect on the severity of disease in PD patients, and does not cause adverse reactions such as hypercalcemia.

In our study, it was verified that there is a certain correlation between VD and H-Y classification. Especially for patients who does not yet exist with motor dysfunction (HY grade < 3), there was a significant negative correlation between serum VD concentration and H-Y grade. Therefore, it can be inferred that VD can be used as an index to predict the severity of PD before PD sports injury. The lower the serum VD concentration in PD patients, the more likely to be exercise impairment.

Sleemana et al [22] study result showed that mean serum 25(OH)D concentrations were lower in PD than control participants at baseline (44.1 ± 21.7 vs. 52.2 ± 22.1 nmol/L, p < 0.05) and 18 months (44.2 ± 23.6 vs. 55.7 ± 28.8 nmol/L, p < 0.05). There was a small but significant association between vitamin D status at baseline and disease motor severity at 36 months.

Our study is consistent with previous study results, and there is a certain correlation between VD and disease course. Especially for patients with a long course of disease (course > 6 months), the course of disease is significantly negatively correlated with serum VD concentration. With the extension of the course of disease, the value of VD in the serum of PD patients will decrease accordingly.

A prospective study [23] showed that there are no support to the hypothesis that vitamin D may reduce the risk of PD. In other words, supplementing VD before the disease cannot reduce the incidence of PD. Meamar [10] et al study confirmed that supplementing VD during PD cannot delay the development of the
disease. Previous reports indicate that there is a significant difference in the biochemical levels of bone metabolism between PD cases and the control group, this may be due to the impact of PD, not the direct role of PD pathogenesis.

Scherzer [24] et al study pointed out that vitamin D has been produced in rats to improve the toxicity induced by 6-hydroxydopamine. Our study also shows that there is a certain correlation between VD and H-Y classification, but the correlation is not significant ($R^2 = 0.4$). Studies have shown that there is a certain polymorphism of VDR in the central nervous system, and this polymorphism affects the impact of VD on its downstream response. However, it is not sufficient to explain the problem only by genetic polymorphism, so further research is needed to confirm it.

There are several limitations in our study. First, our study was conducted on patients and controls in the First Affiliated Hospital of Xinjiang Medical University, not the general Chinese population. The population and ethnic composition of this region and the differences in life are large. It is necessary to evaluate the population lacking vitamin D in other regions of China. Second, because of the relationship between detection methods, our study failed to detect the association between vitamin D from different sources and PD, only to show the correlation between serum VD concentration and PD disease progression, which needs further exploration in the next study. Three, our study is a case-control study and lacks longitudinal clinical evaluation, including multiple vitamin D measurements that fail to assess the relationship between vitamin D status (and its changes over time) and disease progression. In order to provide valuable information, the time window is essential for adequate exposure of vitamin D to prevent or delay the onset of PD. It is necessary to study the longitudinal cohort at different periods to provide valuable information.

**Conclusion**

In our study, the finding of a high incidence of vitamin D deficiency in the PD. High-risk PD patients with vitamin D deficiency who have not yet developed exercise impairment, these should undergo vitamin D measurement and vitamin D treatment as soon as possible. Particularly in elderly patients, the deficiency is closely related to the content of vitamin D.

**Abbreviations**

PD
Parkinson disease; 25(OH) D: 25-hydroxy-vitamin D; HY: Hoehn and Yahr;
LDL-C
Low-density lipoprotein-cholesterol;

**Declarations**

**Acknowledgments**
This research was funded by the National Natural Science Foundation of China (U1603381, 81760043).

Authors’ contributions
M.X. and W.J.X. conceptualized the current study objectives, analyzed the data, and wrote the manuscript draft. X.X. and Q.J.Z. had responsibility of the final content. All co-authors read and approved the final manuscript and were involved in the conception of the research plan.

Funding
Not applicable.

Availability of data and materials
The datasets for this manuscript are not publicly available because of restrictions. Related to the Research Ethics Board requirements.

Ethics approval and consent to participate
The study protocol was approved by the institutional review boards of Ethics Committee of First Affiliated Hospital of Xinjiang Medical University.

Consent for publication
Not applicable.

Competing interests
The authors declare having no competing interests.

Author details
1Department of Neurosurgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054 P.R., China. 2Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054 P.R., China. 3Department of Outpaient, Xinjiang Production and Construction Crops 13 division Red Star Hospital, Hami, 839000 P.R., China. 4Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Key Laboratory of Cardiac Injury and Repair of Henan Province, Zhengzhou, 450002, P.R., China.

References
1. Olanow CW, Stern MBSK. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2006;72, S1–136.
2. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.
3. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348–52.

4. Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini LA, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013;81:1531–7.

5. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67:808–11.

6. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;3:266–81.

7. Bogh MK, Schmedes AV, Philipsen PA, Thieden E, Wulf HC. Vitamin D production depends on ultraviolet-B dose but not on dose rate: a randomized controlled trial. Exp Dermatol. 2011;20:14–8.

8. Wang J, Yang D, Yu Y, Shao G, Wang Q. Vitamin D and Sunlight Exposure in Newly-Diagnosed Parkinson's Disease. Nutrients. 2016; 8:142.

9. Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson's disease a pilot study. Mov Disord. 2013;28:1133–7.

10. Meamar R, Maracy M, Chitsaz A, Ghazvini MR, Izadi M, Tanhaei AP. Association between serum biochemical levels related to bone metabolism and Parkinson's disease. J Res Med Sci. 2013;18:39–42.

11. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord. 2005;12:1598–603.

12. Lian XY, Meng ZD. Relationship between quantity of illumination and human vitamin D concentration and bone mineral density in different region. Chin J Osteoporos. 2011;18:183–7.

13. Parkinson's Disease and Dyskinesia Group. Branch N. Chinese Medical Association. Diagnostic criteria for Parkinson's disease in China. Chin J Neurol. 2006;49:268–71.

14. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.

15. Institute of Medicine of the National Academies. Dietary Reference Intakes for Calcium and Vitamin D; Catharine Ross, Taylor A, Yaktine CL, AL, editors; The National Academy of Sciences: Washington, DC, USA, 2011.

16. Wacker M, Holick MF. Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5:111–48.

17. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology. 1997;49:273–1278.
18. Sato Y, Kaji M, Tsuru T, Satoh K, Kondo I. Vitamin K deficiency and osteopenia in vitamin D-deficient elderly women with Parkinson's disease. Arch Phys Med Rehabil. 2002;83:86-91.

19. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Kawasaki K, Noya M, Takahashi D, Urashima M. 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Mov Disord. 2012;27:264–71.

20. Wang L, Evatt ML, Maldonado LG, Perry WR, Ritchie JC, Beecham GW, Martin ER. Haines JL. Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord. 2015;30:560–6.

21. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Noya M, Takahashi D, Urashima M. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr. 2013;97:1004–13.

22. Sleeman I, Aspray T, Lawson R, Coleman S, Duncan G, Khoo TK, Schoenmakers I, Rochester L, Burn D, Yarnall A. The Role of Vitamin D in Disease Progression in Early Parkinson's Disease. J Parkinsons Dis. 2017;7:669–75.

23. Shrestha S, Lutsey PL, Alonso A, Huang X, Mosley TH. Chen HL. Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk. Mov Disord. 2016;31:972–8.

24. Scherzer CR, Eklund AC, Morse LJ, Liao ZX, Locascio JJ, Fefer D, Schwarzchild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV. Gullans R. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci. 2007;104:955–60.

**Figures**
Figure 1

Plasma levels of total 25(OH) D in PD Relations between total 25(OH) D plasma levels and PD, HY stage (≥3 or ≥3), and disease duration are visualized. Solid line represents fitted correlation between vitamin D levels and symptom duration, HY = Hoehn and Yahr; 25(OH) D = 25-hydroxy-vitamin D; PD = Parkinson disease;